Diamond nanostructures for drug delivery, bioimaging, and biosensing by Chen, Xianfeng & Zhang, Wenjun
  
 
 
 
Edinburgh Research Explorer 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Diamond nanostructures for drug delivery, bioimaging, and
biosensing
Citation for published version:
Chen, X & Zhang, W 2017, 'Diamond nanostructures for drug delivery, bioimaging, and biosensing'
Chemical Society Reviews, vol. 46, pp. 734-760. DOI: 10.1039/c6cs00109b
Digital Object Identifier (DOI):
10.1039/c6cs00109b
Link:
Link to publication record in Edinburgh Research Explorer
Document Version:
Peer reviewed version
Published In:
Chemical Society Reviews
General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s)
and / or other copyright owners and it is a condition of accessing these publications that users recognise and
abide by the legal requirements associated with these rights.
Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer
content complies with UK legislation. If you believe that the public display of this file breaches copyright please
contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and
investigate your claim.
Download date: 05. Apr. 2019
1 
 
Diamond nanostructures for drug delivery, bioimaging, and biosensing 
Xianfeng Chena* and Wenjun Zhangb* 
aInstitute for Bioengineering, School of Engineering, The University of Edinburgh, King’s 
Buildings, Mayfield Road, Edinburgh EH9 3JL, United Kingdom 
bCenter of Super-Diamond and Advanced Films (COSDAF) and Department of Physics and 
Materials Science, City University of Hong Kong, Hong Kong SAR 
*E-mail: xianfeng.chen@oxon.org; apwjzh@cityu.edu.hk 
 
Abstract 
Diamond features an attractive combination of outstanding mechanical, optical, thermal and 
electrical properties; tunable surface characteristics; and unprecedented biocompatibility. 
Additionally, diamond can possess unique nitrogen-vacancy emission centers that are highly 
photostable and extremely sensitive to magnetic fields, temperatures, ion concentrations, and 
spin densities. With these inherent merits, diamond in various nanoscale configurations has 
demonstrated a variety of distinctive applications in a broad range of fields. In particular, 
research on diamond nanoparticles (0-dimensional structures) and arrays of diamond 
nanoneedles/nanowires (1-dimensional structures) has witnessed important and exciting 
progress in recent years. Here, we systematically review the superior properties of diamond 
nanomaterials and the nitrogen-vacancy centers they contain as well as their uses in biomedical 
applications, including biosensing, bioimaging and drug delivery. Moreover, systematic 
studies of the biocompatibility and toxicity of diamond nanostructures, which constitute an 
important issue for the biomedical applications of diamond that has not yet been thoroughly 
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addressed in previous reviews, are also discussed. Finally, we present our insights into the key 
issues concerning these diamond nanomaterials and their future development for applications. 
 
1. Introduction 
Diamond symbolizes wealth and luxury. Although very expensive in cost, it is a valuable 
engineering material with important applications in high-tech electronics, optics and 
machining.1-5 In particular, with the development of high-pressure, high-temperature (HPHT) 
and chemical vapor deposition (CVD) methods, it has become possible to artificially produce 
bulk diamond and 2-dimensional (2D) diamond films,6-10 thereby substantially expanding the 
scope of utilization of this luxury material to a variety of ordinary commercial products. For 
example, diamond lenses enable optical applications under high-power radiation and in harsh 
environments.11 Synthetic diamond is also highly desirable for thermal management and 
semiconductor packaging because of its high thermal conductivity combined with electrical 
isolation.12-16 Furthermore, diamond materials have been developed for high-temperature field-
effect transistors (FETs)17 and surgical knives.18 
Beyond bulk and 2D diamond materials, recent explorations of 1D diamond nanowires 
and 0D diamond nanoparticles have further broadened the applications of this material.19-21 In 
this review, the term “diamond nanoparticles” is used refer to diamond crystals with diameters 
in a range of greater than 1 nm to approximately 100 nm, which are also called simply 
nanodiamonds. Fig. 1a shows atomic force microscopy (AFM) images of individual 5-nm 
diamond nanoparticles.22 Fig. 1b presents a magnified image of a representative nanodiamond 
of 5 nm in height. Regarding 1D diamond nanostructures, this review focuses on vertically 
aligned nanowire, nanoneedle or nanopillar arrays and similar structures formed on flat solid 
substrates. Fig. 1c and d present scanning electron microscopy (SEM) images of diamond 
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nanoneedle arrays fabricated on silicon substrates.19, 20, 23 Below, the fabrication of these types 
of diamond nanostructures is briefly described. 
Diamond nanoparticles can be prepared from molecules of explosives.21 The explosives 
act as a source of carbon and also provide energy for the carbon’s conversion into diamond. 
For example, to synthesize diamond nanoparticles, an oxygen-deficient explosive mixture of 
60 wt% TNT (C6H2(NO2)3CH3) and 40 wt% hexogen (C3H6N6O6) can be detonated in a closed 
metallic chamber in an atmosphere of nitrogen, carbon dioxide and liquid or solid water.21 The 
product comprises diamond nanoparticles of 4-5 nm in diameter and other carbon allotropes as 
well as impurities such as metal. To remove non-diamond carbon, the product can be treated 
using liquid oxidants, such as a mixture of H2SO4 and HNO3. An alternative approach is to 
oxidize the non-diamond carbon in air or ozone-enriched air at elevated temperatures.24, 25 
Compared with liquid-phase purification, the oxidation method is more cost-effective and 
environmentally friendly. 
Vertically aligned diamond nanostructure arrays are commonly produced via a top-down 
process through plasma etching.26, 27 Typically, fabrication is performed via a two-step process 
consisting of the synthesis of diamond films via CVD on a substrate such as silicon followed 
by plasma etching to obtain the desired nanostructures, depending on the etching parameters. 
Because of the negative electron affinity of a hydrogen-terminated diamond surface, this 
plasma etching can be conveniently performed even without the assistance of a mask. The 
diamond films can be either polycrystalline or nanocrystalline in nature. For instance, aligned 
diamond nanostructures have been constructed on [001]-oriented diamond films and HPHT 
diamond single crystals. In these cases, the individual diamond nanostructures (e.g., nanocones 
and nanopillars) that are fabricated still maintain the single-crystal orientation of the starting 
materials.26 
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Diamond nanoparticles and vertically aligned diamond nanostructures inherit the 
remarkable mechanical, optical, thermal and electrical properties, the color centers, and the 
intrinsic biocompatibility of bulk diamond. As a result, these novel nanostructures have a great 
variety of applications, including chromatography, mass spectrometry, proteomics, energy 
storage, catalysis, electroanalysis, tribology and lubrication, tissue scaffolds, surgical implants, 
capacitors and batteries.21 Moreover, nitrogen-vacancy (NV) color centers can be created in 
these diamond nanostructures.28 The superior and unique characteristics of these NV centers, 
together with the excellent biocompatibility and surface tunability of diamond, have led to 
exciting advances in the biological and biomedical applications of diamond nanostructures. 
The progress achieved in research on diamond nanostructures has not only motivated great 
efforts from material scientists but also attracted broad interest from researchers in the fields 
of physics, chemistry, biology, and medicine.  
This review focuses on the properties and applications of 0D diamond nanoparticles and 
arrays of vertically aligned 1D diamond nanostructures for drug delivery, bioimaging and 
biosensing. Because these applications are mainly enabled by the mechanical properties, 
surface modification capability, and biocompatibility of diamond, we first summarize the 
relevant studies on these properties, particularly for diamond nanostructures. Then, we 
introduce NV centers and their unique characteristics, which serve as the basis for the broad 
application of these materials in bioimaging and biosensing. In the subsequent sections, the 
recent progress on the utilization of two types of diamond nanostructures, namely, diamond 
nanoparticles and vertically aligned 1D diamond nanostructures, are surveyed with a focus on 
drug delivery, bioimaging and biosensing. For these applications, the biocompatibility and 
toxicity of these diamond nanostructures are of central importance; therefore, relevant studies 
on these topics are also systematically discussed. After this comprehensive overview, insights 
are presented regarding the future development of these two forms of diamond nanostructures. 
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2. Properties of diamond and diamond nanostructures 
2.1. Mechanical properties 
Diamond is the hardest material in the world; its excellent mechanical properties make it 
very useful and sometimes uniquely suitable for application when mechanical strength is 
required, even at the nanometer scale. As one relevant comparison, the Young’s moduli of 
single-crystal diamond and silicon are 1141 and 162.9 GPa, respectively.29 The Young’s 
modulus and hardness values of diamond materials (e.g., HPHT crystals and films) vary 
depending on the sample preparation method used and the crystallographic orientations, and 
they are also affected by the measurement method and computing approach.30 In general, a 
hardness of 95-131 GPa is well accepted for diamond. These superior mechanical properties 
make diamond an optimal choice for nano-mechanical design.31 For diamond nanowires with 
a cross-sectional area of only 4.58 nm2, at room temperature (300 K), the Young’s modulus, 
yield strength, and fracture strength are still as high as 688, 63, and 91 GPa, respectively (Table 
1).32 The mechanical strength remains high even when the cross-sectional area decreases to 
only 2 nm2 (Table 2).32 At a diameter of greater than 3 nm, diamond nanorods are stronger than 
single-walled carbon nanotubes.33 
Table 1 Mechanical properties calculated under different temperature conditions for 
diamond nanowires (DNWs) with cross-sectional areas of 4.58 nm2.32 
Temperature (K) 100 200 300 400 500 
Yield strength (GPa) 74 68 63 54 53 
Young’s modulus (GPa) 831 753 688 633 583 
Fracture strength (GPa) 122 112 91 80 68 
Fracture strain 0.45 0.41 0.35 0.31 0.25 
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Table 2 Mechanical properties of diamond nanowires with cross-sectional areas ranging 
from 2 to 12.7 nm2 at a temperature of 300 K.32 
Cross-sectional area (nm2) Yield 
strength 
(GPa) 
Young’s 
modulus 
(GPa) 
Fracture 
strength 
(GPa) 
Fracture 
strain 
2.0 29 425 45 0.19 
3.2 55 635 74 0.31 
4.6 63 688 82 0.33 
6.2 72 764 91 0.34 
8.1 75 825 98 0.31 
10.3 79 834 106 0.35 
12.7 80 849 111 0.31 
Bulk diamond 183 1014 183 0.35 
 
2.2. Surface modification  
The surfaces of diamond nanostructures play an important role in determining the utility 
and biocompatibility of these nanostructures in biological and medical applications, such as 
targeted drug delivery, selective biosensing, and effective therapy. The first step of diamond 
surface modification often involves harsh treatment with strong chemicals or plasma irradiation 
to introduce functional groups onto the surface. Once surface functional groups have been 
established, various linker molecules or biomolecules, including biomarkers, therapeutic drugs, 
and genes, can be grafted onto the surface. A range of methods34-42 have been reviewed by 
Nagl et al. with an illustration provided in Fig. 2.43 A number of representative surface 
modification methods are briefly described as follows: 1) Oxidative treatment can create 
carboxyl groups, which are characteristic of the most highly oxidized state of a carbon surface, 
on the surface of diamond, thereby allowing further connection with alcohol or amine 
derivatives.44 Such oxidation is generally performed in a mixture of strongly oxidizing acids, 
such as equal amounts of H2SO4, HNO3, and HClO4 or HCl, HNO3, and H2SO4.
24, 45, 46 
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Alternatively, oxidative treatment can also be performed in a mixture of sulfuric acid and 
hydrogen peroxide with a volume ratio of 3 to 1.47 2) Halogenation, such as thermal or plasma 
fluorination, of the surface enables diamond to react with lithium organic compounds, resulting 
in amino or acid terminations.42, 48-50 3) Oxygen-containing groups carrying C=O moieties on 
the surface of diamond can be reduced to –OH with borane, which permits the subsequent 
growth of various silanes, including assorted foundational groups such as epoxy, amino, sulfido, 
methacryloxy, carboxyl, and PEG groups.34 4) The surface of diamond can be hydrogenated at 
elevated temperatures or in a hydrogen plasma to produce C-H bonds.51 5) The thiolation of 
diamond nanoparticles can also be performed.52 Such thiolation is achieved via a two-step 
process. First, detonation diamond nanoparticles are treated with LiAlH4 to reduce the surface 
carboxyl and carbonyl groups and to generate hydroxyl groups. Second, the hydroxyl groups 
are converted into thiol groups by means of treatment with hydrobromic acid and acetic acid. 
Additional methods for the surface modification of diamond can be found in the reviews by 
Krueger et al.46, 53, 54 and Mochalin et al.21 As can be seen from this summary, the surface of 
diamond can be flexibly tuned depending on the facilities available and the needs of the 
application. 
2.3. Biocompatibility of diamond 
Diamond is chemically inert and does not release toxic chemicals even in harsh 
environments; thus, these properties endow diamond nanostructures with intrinsic 
biocompatibility. This represents a considerable advantage of diamond nanostructures 
compared with II-VI semiconductor quantum dots, which often contain toxic heavy metals; 
consequently, their oxidation leads to slow liberation of heavy metal ions, correspondingly 
giving rise to high toxicity.55-57 Extensive studies have been conducted to explore the in vitro 
and in vivo toxicity of diamond nanostructures.58-61 Overall, the results suggest that diamond 
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nanostructures exhibit extremely high biocompatibility. The details will be discussed in a later 
section. 
3. Nitrogen-vacancy centers in diamond 
Methods of biological labeling and sensing have received significant interest because of 
their applications in not only basic cell biology research but also cancer diagnosis and imaging. 
Extensive efforts have been devoted to this field, and a variety of nanomaterials have been 
developed for this purpose.62-70 For instance, II-VI semiconductor quantum dots have been 
extensively studied for bioimaging and sensing applications.64, 71 However, this group of 
materials generally suffers from the problems of photobleaching, photoblinking, and 
particularly cytotoxicity, which severely limit their use to mostly in vitro work and narrow their 
scope of application.72 To overcome these limitations, silicon nanocrystals and carbon dots, 
which feature higher photostability and better biocompatibility, have been developed.73-80 
Although silicon nanocrystals and carbon dots have demonstrated increasing importance in the 
field of biological labeling and sensing, important questions still remain regarding a complete 
understanding of their fluorescence mechanism and rational control of their emission 
characteristics. Unlike these materials, the biological labeling and sensing behavior of diamond 
nanoparticles is known to rely mainly on the formation of well-established fluorescent NV 
centers. Together with the facile surface modification and excellent photostability and 
biocompatibility of diamond nanoparticles, the high sensitivity of NV centers endows these 
nanoparticles with unprecedented performance in bioimaging and biosensing. In this section, 
the general nature, methods of production, and characteristics of NV centers are summarized. 
3.1. The nature of nitrogen-vacancy centers  
NV centers are a type of point defect in diamond. As shown in Fig. 3a, an NV center is 
composed of a substitutional nitrogen atom (blue ball) and a bounded lattice vacancy (white 
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ball).28 NV centers in diamond are luminescent color centers. A high concentration of NV 
centers lends a pink color to a diamond crystal. 
A single NV center may carry a negative charge or may possess a neutral charge state, 
denoted by NV- and NV0, respectively. When excited by green light (532 nm), such a color 
center emits in the near-infrared region. The fluorescence spectrum of a single NV center 
exhibits zero-phonon lines (ZPLs) that are characteristic of NV0 and NV- (Fig. 3b).28 
In the neutral charge state, an NV defect has one unpaired electron. In the negative charge 
state, an NV defect has two unpaired electrons, which form an integer spin (S=1), and the defect 
has associated electron energy levels of triplet ground (3A) and excited (3E) states (here, the 
number 3 indicates that 3 ms spin states of -1, 0, and 1 are allowed). In the absence of an 
external magnetic field, the ground-state spin sublevels corresponding to ms=1 are degenerate 
and separated from ms=0 (the ms=1 levels have similar energies). Upon excitation with light 
(green arrow), electrons are excited from the 3A state to the 3E state. Subsequently, the electrons 
return from the 3E state to the 3A state and release energy by emitting light (red arrows). During 
these processes, the transitions between the ground and excited states conserve the spin state 
of ms=0 or 1. On occasion, the excited state (3E) may transition into a metastable singlet state 
(1A), from which the electrons will return to the ground state through non-radiative emission 
(black arrows). The excited states corresponding to ms=1 have a higher probability of inter-
system crossing. 
In the presence of a resonant magnetic field, the ms=1 energy levels shift in opposite 
directions (the difference between these two energy levels increases), and the electron spin 
undergoes a transition from ms=0 to ms=1 in the ground state (Fig. 3c).28 This leads to more 
inter-system crossing and, correspondingly, to a dramatic decrease in fluorescence emission 
intensity. From the description given above, it can be seen that the spin state of the electrons in 
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an NV center can be conveniently determined based on fluorescence variations, namely, 
through optically detected magnetic resonance (ODMR). Fig. 3d shows the ODMR spectra of 
a single NV spin under different magnetic fields.28 It is clear that an external magnetic field 
causes the energy levels of the NV electron spin states to split. An important feature of ODMR 
is that it can be detected at the single-spin level under ambient conditions, such as room 
temperature.  
As described above, the electron spin states of NV centers are very sensitive to magnetic 
fields. This phenomenon can be conveniently exploited for sensing subtle changes. Fig. 4a 
shows the setup for a magnetic field imaging experiment.81 In this setup, a diamond nanocrystal 
containing a single NV center is attached to the tip of an AFM cantilever, which is used to 
profile the magnetic field generated by a small magnetic structure at the nanometer scale. Fig. 
4b presents an optical image of a diamond nanocrystal mounted on an AFM tip. Fig. 4c presents 
an AFM image of the magnetic nanostructure at the top and a corresponding magneto-optical 
image of the same magnetic structure at the bottom. In this demonstrative work, a single NV 
center was employed as an atomic-scale magnetic field sensor. The spatial resolution associated 
with the size of diamond nanoparticles can be as small as a few nanometers or even at the sub-
nanometer level, thus offering a sufficiently high sensitivity to probe single electron spins.82, 83 
In addition to magnetic fields, the spin states of NV centers, particularly NV- centers, are 
also sensitive to interfering factors such as temperature, ion concentration, electric fields, and 
crystal stress. Because of these unique properties, the fluorescence signals from NV- centers 
can be used as a sensitive probe in a variety of applications. 
3.2. Production of nitrogen-vacancy centers 
In diamond nanoparticles with a negligible concentration of nitrogen, NV centers can be 
created via N+ ion implantation followed by annealing at high temperatures.84 By contrast, if a 
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diamond material already contains nitrogen impurities, then NV centers can be generated via 
particle irradiation followed by annealing. Various types of high-energy particles have been 
used for this purpose, such as electrons, protons, ions, and neutrons. An example of a procedure 
for producing NV centers via proton irradiation is as follows:85 1) synthetic type Ib (typical 
nitrogen concentration of 100 ppm) diamond powders of approximately 100 nm in size are 
processed in strong oxidative acids; 2) a diamond powder film is prepared by depositing the 
purified diamond suspension on a silicon wafer, followed by drying; and 3) the diamond 
powder film is irradiated with a 3-MeV proton beam at a dose of 51015 ions/cm2 and then 
subjected to annealing at 800 C in vacuum. It is understood that irradiation creates vacancies 
in a diamond lattice, whereas high-temperature annealing drives the migration of the vacancies 
to nitrogen impurities, thereby leading to the development of NV color centers. This method 
produces a concentration of NV centers of approximately 1107 centers/µm3, which is 
equivalent to approximately 1104 centers per 100-nm diamond nanoparticle. Upon excitation 
with green light, the emission of the diamond nanoparticles spans wavelengths from 600 to 800 
nm. Compared with nanodiamonds produced using the same procedure but without exposure 
to proton irradiation, irradiated diamond nanoparticles possess a fluorescence intensity that is 
100 times stronger.85  
Despite the success achieved using such procedures, high-energy irradiation and vacuum 
annealing at elevated temperatures require sophisticated and costly facilities. To address this 
problem, Chang et al. reported a method of mass-producing diamond nanoparticles with high 
fluorescence.86 In this approach, the nanodiamonds are synthesized through ion bombardment 
(irradiation) of synthetic type Ib diamond powders using 40-keV He+ ions at a dose of 
approximately 1x1013 ions/cm2. He+ ions have a very high damaging efficacy; a 40-keV He+ 
ion is able to produce 40 vacancies in diamond, whereas a 2-MeV e- or a 3-MeV H+ ion can 
generate only 0.1 or 13 vacancies, respectively.87, 88 Thus, the stronger damaging capability of 
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40-keV He+ bombardment can considerably reduce the required ion dose and facilitate the 
large-scale production of NV centers in diamond nanoparticles. 
To further reduce the cost of NV center production, Baranov et al. reported an alternative 
approach for generating a high concentration of fluorescent NV- centers through the HPHT 
sintering of diamond nanoparticles of approximately 4-5 nm in size.89 In this method, 
commercial diamond nanoparticles are first purified in highly concentrated hydrochloric acid 
(HCl) with the aid of ultrasonication. Then, the nanoparticle suspension is repeatedly treated 
with 38% HCl, followed by washing in boiling distilled water. Finally, the diamond powder is 
sintered in an HPHT system at 800 °C under a pressure of 6 GPa for 11 s. This method enables 
the production of a very high concentration of NV- centers, i.e., up to one NV- center per nm3. 
3.3. Characteristics of nitrogen-vacancy centers 
To track and image a single molecule or particle within a cell using fluorescent probes, it 
is usually necessary to avoid interference from the fluorescence of various ubiquitous 
endogenous components, including collagens, porphyrins, and flavins. Typically, these 
molecules absorb light at wavelengths ranging from 300 to 500 nm and emit at wavelengths 
between 400 and 550 nm. Diamond nanoparticles exhibit emission ranging mainly from 550 
to 800 nm under excitation with green light, making diamond nanoparticles a desirable probe 
for bioimaging (Fig. 3a).28, 85, 86, 90-92 Within this wavelength range, to get a strong signal in 
imaging, it is still required that the fluorescence probe should possess strong absorption and 
emission. In line with this, NV- centers in diamond nanoparticles exhibit strong absorption at 
approximately 560 nm and emission at approximately 700 nm. The absorption cross section of 
such an NV- center at the band center has been reported to be approximately 5×10-17 cm2, which 
is comparable to that of dye molecules.85, 93 One recent study has shown that the absorption 
cross section of an NV center at a wavelength of 532 nm is (0.95±0.25)×10-16 cm2.94 It has been 
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demonstrated that a single 11-nm diamond nanoparticle containing 3 NV- centers possesses 
dramatically stronger photoluminescence than does a single molecule of the red fluorescent 
protein DsRed-Monomer.95 Moreover, fluorescence lifetime measurements indicate that the 
fluorescence decay of diamond nanoparticles has a fast component of 1.7 ns (4%) and a slow 
component of 17 ns (96%), as shown in Fig. 5a.90 The latter value is much longer than those 
for Alexa Fluor 546 (approximately 4 ns) and cell and tissue autofluorescence (approximately 
3 ns), which is particularly beneficial for isolating the emission of diamond nanoparticles from 
the background signals with the assistance of time-gating approaches.96-98 
Photostability is another important factor to be considered with regard to fluorescent 
probes used in biosensing applications. Yu et al. demonstrated that fluorescent nanodiamonds 
possess much better photostability than do polystyrene nanospheres.79 In this experiment, no 
sign of photobleaching was observed in the nanodiamonds even after 8 hours of continuous 
illumination under an Hg lamp. In stark contrast, under the same excitation conditions, the 
fluorescence of 0.1-µm red fluorescent polystyrene nanospheres decreased to nearly zero after 
only 0.5 h of illumination.85 Similarly, Fu et al. studied the fluorescence properties of 
individual diamond nanoparticles using Alexa Fluor 546 as a reference.90 The results indicated 
that both 100- and 35-nm diamond nanoparticles possess excellent photostability over a period 
of 300 seconds under 532-nm excitation at a power density of 8103 W/cm2, whereas single 
molecules of Alexa Fluor 546 suffer bleaching of their fluorescence within only 12 seconds 
(Fig. 5b). 
Gruber et al. have also shown that the fluorescence of NV centers is highly stable even 
under excitation at an extremely high power of 5 MW/cm2.99 In contrast to the outstanding 
photostability of nanodiamonds, the photobleaching of quantum dots has been widely reported. 
For instance, under exposure to an Ar-Kr continuous wave (CW) laser operating at 468 nm and 
20 kW/cm2, core/shell CdSe/ZnS quantum dots have been found to experience photobleaching 
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after approximately 2-3 min in air and 10-15 min in nitrogen.100, 101 Moreover, the 
photobleaching of carbon dots has also been observed even under much weaker illumination.102 
The observed excellent photostability of nanodiamonds is considered to be due to the 
localization of the excited state of each color center around the corresponding impurity atom, 
whereas in a quantum dot, the excited state is delocalized over its entire volume. In addition, 
the energy levels of the color centers in diamond are well separated from the valence and 
conduction bands of the material, which leads to the trapping of photoelectrons within these 
energy levels, even under high-power laser illumination.103 
In addition to the above good characteristics to achieve high quality imaging, diamond 
nanoparticles also possess the following advantages that are very useful for quantitative 
analysis. Firstly, unlike that of other fluorescent nanomaterials such as semiconductor quantum 
dots, silicon nanocrystals and carbon dots, the fluorescence of diamond nanoparticles is not 
sensitive to surface modification and functionalization. The reason for this insensitivity is that 
the fluorescence of a diamond nanostructure originates from point defects within the interior 
of the structure.85, 90 As shown in Fig. 6a, under irradiation with 3-MeV H+ ions and 40-keV 
He+ ions, the fluorescence intensities are different because of the different concentrations of 
NV centers generated by the irradiation, but the emission spectra have nearly the same profile. 
Fig. 6b further demonstrates that the fluorescence intensities of diamond nanoparticles of three 
different sizes show a similar linear dependence on the excitation laser power.86 These 
observations suggest that the fluorescence intensities of diamond nanoparticles depend on their 
bulk properties, with negligible influence from the particles’ surface characteristics. By 
contrast, the fluorescence properties of semiconductor quantum dots, silicon nanocrystals and 
carbon dots, including their emission peaks and intensities, are dramatically influenced by 
surface modification and their working environments,104-107 and this sensitivity can cause 
serious problems in the interpretation of spectroscopic results and quantitative analysis. It is 
15 
 
worth nothing here that the emission spectrum profile can still be easily tuned by conjugating 
with fluorescent dyes108 or semiconductor quantum dots109 if needed to lend their flexibility in 
applications. 
 Secondly, it has also been observed that diamond nanoparticles do not exhibit 
fluorescence blinking at a time resolution of 1 ms.90 Because photoblinking may cause 
fluctuations in fluorescence intensity and thus cause difficulties in quantitative analysis, the 
non-blinking behavior of diamond nanoparticles is another aspect in which diamond 
nanoparticles are superior to semiconductor quantum dots and silicon nanocrystals, which both 
exhibit photoblinking.110-113  
4. Diamond nanoparticles for bioimaging, biosensing and drug delivery 
4.1. Fluorescence imaging 
Diamond nanoparticles have been widely employed for fluorescence imaging in various 
applications because of their collectively outstanding properties. Fig. 7a shows an overlay of 
bright-field and fluorescence images of a HeLa cell after the internalization of fluorescent 
nanodiamonds. The image indicates that the diamond nanoparticles are predominantly located 
in the cytoplasm of the cell after intracellular uptake. In the corresponding fluorescence image 
presented in Fig. 7b, two individual diamond nanoparticles separated by 1 m can be 
identified.90 Because of their high brightness and photostability, the motion of individual 
diamond nanoparticles can be tracked over long durations. For example, Fu et al. tracked a 
diamond nanoparticle for 13.9 s and found that the particle experienced Brownian motion 
confined with a 11 m2 area.90 In another study by the same group, Chang et al. monitored 
the movement of an individual nanodiamond within a live HeLa cell for more than 200 s (Fig. 
7c).86 Through a mean square displacement analysis of the 3D trajectories, the diffusion 
coefficient of nanoparticles internalized in living cells can be determined.86, 114 Collectively, 
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these experiments demonstrate that fluorescent diamond nanoparticles can be a desirable probe 
for in vivo imaging and long-term tracking as cellular biomarkers. The work illustrated in Fig. 
7c also indicates that the imaging can be realized with high temporal and spatial resolution. To 
prove this, Epperla et al. employed diamond nanoparticles as fluorescent trackers to monitor 
the intracellular transport of proteins through tunneling membrane nanotubes.115 Bovine serum 
albumin (BSA) and green fluorescent protein (GFP) were coated on diamond nanoparticles of 
approximately 100 nm in diameter by means of physical adsorption. The motion of the protein-
decorated diamond nanoparticles through the tunneling nanotubes could be continuously 
monitored for longer than 10 min. Furthermore, Liu et al. recently demonstrated the use of 
protein-conjugated fluorescent diamond nanoparticles as imaging probes. In that work, the 
diamond nanoparticles were modified with transforming growth factor (TGF). Such 
nanoparticles can specifically bind to TGF-beta receptors, which play an important role in 
immune suppression and the metastasis of cancer cells. An understanding of TGF-beta 
receptors and their pathways is very important for the development of cancer therapies. 
Therefore, the authors used TGF-coated diamond nanoparticles to study the trafficking process 
of TGF-beta receptors. This strategy offered localization accuracies of 8 nm in the xy directions 
and 16 nm in the z direction, which are better than those of conventional organic dyes for 3D 
imaging.116 These two examples validate a powerful tool of using fluorescent nanodiamonds 
for long-term imaging of the intracellular delivery of proteins. The understanding of the 
proteins’ transmembrane pathways and mechanisms will greatly contribute to the development 
of better therapeutic medicines to treat diseases. 
 With their superior photostability and improved localization accuracy, diamond 
nanoparticles can also be applied for super-resolution microscopy using the stimulated 
emission depletion (STED) technique.117, 118 Through this method, multiple NV- centers in 
individual diamond nanoparticles can be resolved, and a remarkable resolution of 
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approximately 6-10 nm is achievable (Fig. 7d and e).117, 119, 120 With such an ultra-high 
resolution, the applications of using fluorescent diamond nanoparticles in cell biology are 
expected to be tremendously extended. 
The low exocytosis of fluorescent diamond nanoparticles from cells is another beneficial 
factor enabling their long-term imaging. The extent of exocytosis of fluorescent diamond 
nanoparticles from human cancer cell lines has been determined to be only approximately 15% 
or less after 6 days of labeling in 489-2.1 multipotent stromal cells and HeLa cells.60 By virtue 
of this low exocytosis combined with the advantages of chemical and photophysical stability, 
diamond nanoparticles have been used to track AS-B145-1R breast cancer cells, which is used 
as a model cell line for quiescent cancer stem cells (CSCs), for longer than 20 days.121 For 
comparison, when D-penicillamine-coated CdSe/ZnS core/shell quantum dots (8 nm in 
diameter) were tested in live HeLa cells, a significant fraction of the endocytosed quantum dots 
were exocytosed with a half-life of only 21 min; approximately 50% of the quantum dots were 
exocytosed after 100 min after the nanoparticle incubation solution was replaced with cell 
medium.122 It has also been observed that for silicon quantum dots in human umbilical 
endothelial cells (HUVECs), approximately 60% are removed from cells after 250 min.123 
Moreover, the exocytosis half-life of carbon dots in rat adrenal pheochromocytoma cells and 
rat Schwann cells has been revealed to be approximately 2 hours, with more than 70% of the 
carbon dots having been exocytosed after 1 day.124  
4.2. Magnetic resonance imaging 
Magnetic resonance imaging (MRI) is capable of achieving non-invasive 3D elementally 
selective mapping without radiation and is consequently a widely used technique in medicine 
and neuroscience. However, the spatial resolution of conventional MRI is limited to tens of 
micrometers or even millimeters. Recently, diamond nanoparticles with NV centers have been 
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employed for MRI.82, 83, 125-131 Because of the high sensitivity of the electron spin states of NV 
centers to magnetic fields, a considerable improvement in the resolution of MRI has thus been 
demonstrated, bringing this resolution to the nanometer level. 
Grinolds et al. developed the first 3D spatial mapping technique for dark electronic spins 
on and near a diamond surface, in which lateral and vertical resolutions of 0.8 and 1.5 nm, 
respectively, were demonstrated.83 In addition to electron spins, NV- centers have also been 
employed to sense nuclear spins, which have magnetic moments that are at least 600 times 
smaller than those of electron spins. Rugar et al. utilized NV centers to detect the oscillating 
magnetic field generated by protons and demonstrated a spatial resolution of 12 nm for the 2D 
1H NMR imaging of a poly(methyl methacrylate) (PMMA) sample using a single NV center 
in diamond.82 Similarly, using a single NV center embedded at approximately 7 nanometers 
below the surface of a bulk diamond, Staudacher et al. detected 1H nuclear spins from single 
(5-nm)3 voxels of various fluid and solid organic samples under ambient conditions.132 In 
addition to detecting 1H nuclear spins, Devience et al. showed that NV centers in diamond can 
be used in NMR spectroscopy and MRI for detecting various nuclear species, including 1H, 19F, 
and 31P, in non-uniform samples (with varying concentrations of nuclear spins) under ambient 
conditions.126 Zhao et al. and Müller et al. further demonstrated that NV centers can be applied 
to achieve single-nucleus sensitivity to 13C and 29Si spins.127, 133 With these demonstrated ultra-
high resolution of NV-center-based MRI, we not only extend its application to the study of the 
structures of samples at the molecular level but also enhances its practical applicability in the 
life sciences and healthcare. McGuinness et al. pioneered the tracking of individual fluorescent 
nanodiamond NV centers within living HeLa cells by detecting their magnetic resonance. In 
this manner, the locations, orientations, spin levels and spin coherence times of NV centers can 
be measured with nanoscale precision.134 NV centers have also been employed for the imaging 
of bioprocesses and the sensing of biomolecules.28, 128, 135-138 For instance, by using diamond 
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nanoparticles with NV centers, the operation of cell membrane ion channels can be monitored 
with a temporal resolution of 1-10 milliseconds and a spatial resolution of nanometers.139 Very 
attractively, this method enables single-protein detection.140 By virtue of its inherent 
advantages, it is expected that NV-center-based MRI technology can be applied to probe 
intracellular electrons and, potentially, nuclear spins in single biological molecules (Fig. 8).28 
4.3. Sensing based on optically detected magnetic resonance  
As described in Section 3.1, ODMR allows diamond nanoparticles with NV centers to 
respond in an ultrasensitive way to external interfering parameters that can affect the spin states 
of NV- centers. One potential application of this technique is to measure environmental 
temperature changes using nanodiamonds as quantum thermometers. It is always challenging 
to probe temperature variations within a local volume at the nanometer scale, particularly in 
living systems. Kucsko et al. demonstrated the ability to monitor local temperature variations 
in a living human embryonic fibroblast using nanodiamonds as probes.141 The experimental 
design is illustrated in Fig. 9a-b. In this experiment, nanodiamonds and gold nanoparticles were 
introduced into the cell. The gold nanoparticles absorbed the energy of laser illumination, 
thereby enabling control of the local temperature, and precise spectra of the NV spins in the 
nanodiamonds were collected to realize temperature mapping at the subcellular level. Because 
the value of the transition frequency () between the ms = 0 and ms = ±1 states is directly 
related to the temperature (d/dT=-2×77 kHz/K) because of thermally induced lattice strains, 
a temperature measurement precision as small as 1.8 mK and a spatial resolution as small as 
200 nm were demonstrated in this experiment. Compared with other reported approaches, as 
illustrated in Fig. 9c, it is obvious that spectroscopy based on NV centers in nanodiamonds by 
means of ODMR offers an excellent combination of temperature accuracy (1.8±0.3 mK) and 
spatial resolution (approximately 100 nm). Recently, Tzeng et al. also applied this technique 
to achieve the real-time monitoring of temperature variations of over ±100 K.142 
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4.4. Drug and gene delivery using diamond nanoparticles 
4.4.1. Diamond nanoparticles in drug delivery 
Many modern drugs that are therapeutically important suffer from poor water solubility, 
which limits their clinical applications. Various approaches have been explored to solve this 
problem, such as utilizing block-copolymer-stabilized nanoemulsions, polymeric micelles, or 
self-aggregated nanoparticles or loading in liposomes.143-148 As an alternative approach, 
diamond nanoparticles have also been complexed with poorly water-soluble drugs to enhance 
their dispersion in water while maintaining drug activity.149 For instance, Chen et al. showed 
that diamond nanoparticles (4-6 nm in diameter) functionalized with carboxyl groups can 
adsorb drug molecules through physisorption and electrostatic interactions, thereby facilitating 
the dispersion of these molecules in an aqueous solution. The surfaces of diamond 
nanoparticles have been demonstrated to play a key role in how they interface with drug 
molecules. This approach has been applied to enhance the dispersibility in water of various 
drugs with poor water solubility, including purvalanol A for liver cancer treatment, 4-
hydroxytamoxifen for breast cancer therapy, and dexamethasone for anti-inflammation.58  
In addition to in vitro demonstrations, diamond nanoparticles have also been employed to 
deliver various water-insoluble drugs, e.g., sorafenib, for in vivo cancer therapy.150 Sorafenib 
is a potential medicine for the treatment of metastatic gastric cancer. However, it demonstrates 
very poor solubility in water and even in buffered solutions with pH values ranging from 1.2 
to 7.4, resulting in extremely low oral bioavailability. To improve the drug’s dispersion in water, 
sorafenib was mixed with diamond nanoparticles to form diamond-sorafenib clusters. Then, 
these clusters were coated with an amphiphilic lipid, distearoylphosphatidylethanolamine-
poly(ethylene glycol) (DSPE-PEG), as illustrated in Fig. 10a. The efficacy of the lipid-coated 
nanodiamonds loaded with sorafenib (SNDs) was evaluated using tumor xenograft mice as the 
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animal model. The group treated with SNDs displayed significant inhibition of tumor growth 
compared with others treated with an equivalent dose of sorafenib, as presented in Fig. 10b-d. 
In addition, the mice treated with SNDs also showed a dramatic reduction in the number of 
metastatic nodules in the liver and kidneys (Fig. 10e and f).150 The metastasis accounts for over 
90% of cancer-associated death and is one major challenge in cancer therapy, so the 
development of such technology is highly desirable. 
In addition to facilitating the delivery of water-insoluble drugs, nanodiamonds can also be 
used to enhance drug efficacy. In a study by Chow et al., diamond nanoparticles were used to 
aid in the delivery of an anticancer drug, DOX, for treatment in models of drug-resistant breast 
cancer (4T1) and liver cancer (LT2-M). It was found that the tumors expelled the 
nanodiamond-DOX complexes to a lesser extent than they did free DOX molecules, and the 
blood circulation time of the complexes was 10 times longer than that of free DOX molecules. 
The former will allow DOX to be more effective in tumor treatment and the latter increase 
DOX delivery to the tumor. Moreover, the use of nanodiamond-DOX complexes dramatically 
alleviated the problems of severe toxicity and myelosuppression that were observed for the free 
DOX molecules. As a result, the nanodiamond-DOX complexes could efficiently shrink the 
size of the tumors.151 It has also been demonstrated that nanodiamonds can improve DOX 
accumulation in lung tissue and thus inhibit lung metastasis in breast cancer.59 With 
convection-enhanced delivery, a local infusion technique for the direct delivery of drugs to the 
central nervous system, nanodiamond-DOX complexes have been demonstrated to serve as a 
powerful treatment against brain tumors.152 
Besides DOX, many other drugs have been delivered with the assistance of diamond 
nanoparticles. For example, nanodiamonds loaded with daunorubicin (DNR) can overcome 
multidrug chemoresistance in leukemia,153 and epirubicin-adsorbed diamond nanoparticles can 
effectively kill both normal cancer cells and cancer stem cells, resulting in potent inhibition of 
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secondary tumor growth.154 Moreover, Cui et al. used diamond nanoparticles to deliver 
cisplatin155 and found that sodium-alginate-functionalized diamond nanoparticles could 
increase drug accumulation and retention time in tumor cells. 
In addition to single-drug therapies, diamond nanoparticles can also be used to deliver a 
combination of several drugs in a single treatment for a synergistic effect. For instance, Wang 
et al. demonstrated that an optimal combination of nanodiamond-DOX, nanodiamond-
mitoxantrone, nanodiamond-bleomycin, and free paclitaxel resulted in the best therapeutic 
efficacy against multiple breast cancer cell lines among a variety of combinations of free drug 
molecules and nanodiamond-drug molecules.156 
As an alternative to using diamond nanoparticles as carriers for direct drug delivery, it has 
recently been demonstrated that properly surface-modified diamond nanoparticles can be used 
to induce vascular barrier leakiness to indirectly facilitate drug delivery.157 In these experiments, 
a monolayer of endothelial cells was cultured to mimic the vascular barrier in blood vessels. 
Upon treatment with nanodiamonds as illustrated in Fig. 11a, the vascular barrier became leaky 
(Fig. 11b), which allowed an increased amount of DOX to penetrate the vascular barrier and 
consequently led to increased cell death (Fig. 11c and d). The results indicate that –NH2-
modified diamond nanoparticles demonstrate a higher potency in inducing vascular leakage 
compared with bare nanodiamonds or nanodiamonds terminated with –COOH. The leakiness 
was found to be caused by the increased generation of reactive oxygen species (ROS) upon 
treatment with diamond nanoparticles. It remains unknown whether other types of 
nanostructures can also cause leakiness of vascular barriers, although such a result could be 
expected because it is common for the application of nanomaterials to induce ROS 
production.158, 159 Tumors at earlier stages are more responsive to treatment. However, the 
blood vasculature around early-stage tumors is not leaky. Therefore, the ability of diamond 
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nanoparticles with proper surface termination to induce vascular barrier leakiness offers a new 
pathway for the early therapy of cancers. 
The drug delivery work described above makes use of various characteristics of diamond 
nanoparticles, such as their suitable size, high aqueous dispersibility, and ease of surface 
modification. In addition to these characteristics, the outstanding mechanical properties of 
diamond also give rise to several other interesting and unique applications of nanodiamonds in 
clinical medicine. Recently, Lee et al. applied diamond nanoparticles to form a composite with 
gutta-percha for root canal therapy (RCT).160 Gutta-percha is a conventional filler material used 
to fill the root canal space, but it suffers from several limitations, such as a tendency to induce 
root canal reinfection and poor mechanical properties. In the reported approach, the diamond 
nanoparticles were functionalized with amoxicillin to prevent infection. The diamond material 
was chosen to improve the mechanical properties of the filler material. Moreover, Ryu et al. 
have also developed alendronate-conjugated diamond nanoparticles to achieve bone-targeted 
delivery for osteoporosis treatment.161 
4.4.2. Diamond nanoparticles in gene transfection 
Gene therapy provides the opportunity to treat certain diseases that are otherwise difficult 
to cure. In gene therapy, DNA and siRNA must be delivered to the cytoplasm or nuclei of cells 
to be functional. Thus far, a variety of methods have been developed for gene delivery, 
including methods using various nanomaterials.162-165 Diamond nanoparticles have also found 
a role in gene transfection because of their superior properties. Martin et al. treated 
nanodiamonds obtained via detonation with FeSO4 and H2O2 under strong acidic conditions. 
Through this process, the size of the nanoparticles was reduced from 7.20 to 4.77 nm, and their 
surfaces were populated with hydroxyl groups. Subsequently, these nanoparticles were 
modified with triethylammonium and electrostatically paired with negatively charged GFP 
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plasmid DNA for successful gene expression.166 Zhang et al. used polyethyleneimine (PEI800) 
to modify diamond nanoparticles and then applied them for DNA delivery (Fig. 12a). This led 
to a 70-fold increase in transfection compared with PEI800 alone, while the cytotoxicity 
remained very low.167 With this approach, transfection efficiency comparable to that of PEI25K 
can be achieved but with significantly lower cytotoxicity (Fig. 12b and c). This method can 
also be applied for siRNA delivery, and siRNA transferred by diamond nanoparticles 
(approximately 7 nm in diameter) has been found to efficiently inhibit the gene expression of 
EWS/FLI-1 in a Ewing sarcoma cell line.168 The silencing of this gene has been found to 
improve the cytotoxic effect of the anticancer drug vincristine.169, 170 Recently, diamond 
nanoparticles were also shown to be able to deliver cytosine-phosphate-guanine (CpG) 
oligonucleotides (ODNs) for efficient cancer immunotherapy.171 It was found that diamond 
nanoparticles could increase the cellular uptake of CpG ODNs by approximately three orders 
of magnitude. This nanosystem induced long-term immunoregulatory activity that could last 
for 3 days at the cellular level and 2 days in a mouse model. When the nanostructures were 
tested in two murine tumor models, including B16 melanoma and 4T1 breast carcinoma 
xenografts, tumor growth was substantially inhibited. 
When nanomaterials (e.g., nanoparticles) are employed for drug and gene delivery, 
complexes consisting of the drug/gene and the nanomaterial enter cells through endocytosis 
and are then confined in endosomes or lysosomes. Consequently, the escape of the confined 
complexes into the cytoplasm of the cells is essential for them to be effective, but this is often 
a problem for many nanomaterials. To address this issue, Chu et al. fabricated diamond 
nanoparticles with sharp features and demonstrated that these nanodiamonds could easily enter 
cells via micropinocytosis.172 Advantageously, shortly after intracellular uptake, these 
nanodiamonds are capable of rupturing the endosome membrane and escaping into the 
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cytoplasm. This feature makes such nanodiamonds particularly useful for gene and drug 
delivery. 
4.5. Diamond-nanoparticle-based multifunctional platform for combined targeting, 
imaging and therapy 
Based on the ease of surface modification of nanodiamonds with various functional groups, 
including targeted probes and drugs, a multifunctional platform for combined targeting, 
imaging and therapy using diamond nanoparticles has been demonstrated. This combination 
allows simultaneous diagnosis and therapy and also enables monitoring therapeutic delivery, 
transport and response. Zhang et al. reported the functionalization of nanodiamonds with the 
hetero-bifunctional cross-linker sulfosuccinimidyl 6-(3’-[2-pyridyldithio]propionamido) 
hexanoate (sulfo-LC-SPDP) and the subsequent attachment of thiolated antibodies for selective 
targeting as well as drug-oligonucleotide conjugates, including fluorescein labels and 
paclitaxel (PTX), for imaging and chemotherapy, respectively, yielding functionalized 
nanodiamonds abbreviated as PTX-DNA/mAb@NDs, as shown in Fig. 13a.173 The purpose of 
the antibody was to target human epidermal growth factor receptor (EGFR), which is 
overexpressed in many solid tumors, including in lung, colorectal, and breast cancers. PTX is 
a widely used anticancer drug for breast and ovarian cancers. However, it has several 
limitations, such as low solubility in water and drug resistance. Commercial formulations of 
PTX often involve the use of organic solvents that can cause serious side effects; this delivery 
platform can solve this problem while increasing the bio-availability of PTX. The selective 
targeting of the nanomedicine was investigated based on cellular uptake by basal EGFR-
expressing MCF7 cells and the MDA-MB-231 cell line with EGFR overexpression. The flow 
cytometry results (Fig. 13b) show that the PTX-DNA/mAb@NDs entered the MDA-MB-231 
cells very efficiently because of the overexpression of EGFR, which is specifically targeted by 
the antibodies on the surfaces of the PTX-DNA/mAb@NDs, in these cells. When PTX-
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DNA/mAb@NDs and PTX-DNA@NDs were used, improved cytotoxicity was observed 
compared with that observed for PTX only. For the MDA-MB-231 cells, the PTX-
DNA/mAb@NDs appeared to be the most efficient therapy (Fig. 13c). Overall, these results 
suggest that PTX-DNA/mAb@NDs can specifically target cells with EGFR overexpression 
and significantly increase the cellular uptake and therapeutic efficacy of anticancer drugs for 
these cells. In this example of the use of nanodiamonds in a multimodal application, imaging 
was achieved through fluorescence labeling instead of using NV- centers. However, because of 
the superior advantages of these color centers, it is desirable for future research to focus on 
nanodiamonds with NV- centers that can be used for theragnosis. Because of the extremely 
high photostability of these color centers, it should be possible to achieve precision image-
guided therapies. 
4.6. Biocompatibility and toxicity of diamond nanoparticles 
For the adoption of a new material in practical applications, it is essential to thoroughly 
investigate that material’s biocompatibility and toxicity. For use in clinical settings in particular, 
it is necessary to understand the absorption, distribution, metabolism and excretion (ADME) 
characteristics of the material. Because of the superior properties of diamond nanoparticles and 
their correspondingly high potential for use in a large number of applications, numerous studies 
have been performed to investigate their biocompatibility and toxicity. 
Many experiments have been performed in which various concentrations of diamond 
nanostructures have been incubated with various cell lines and the resulting viabilities of the 
cells have been tested. All results indicate that cell viabilities are not negatively affected at 
reasonably high concentrations of nanodiamonds after 2-3 days of incubation.58, 59, 174 For 
example, in the work represented in Fig. 13, over 90% of cells were still alive after incubation 
with diamond nanoparticles at concentrations of up to 200 g/ml. Fang et al. found that the 
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internalization of fluorescent diamond nanoparticles did not lead to any significant alteration 
in the growth and proliferation of HeLa, 3T3-L1 and 489-2.1 cells during 8 days of 
observation.175 Following preliminary cytotoxicity investigations of this type in cell lines, 
many detailed studies have also focused on gaining a full understanding of the influence of 
nanodiamonds on cell physiology as well as their long-term toxicity in worm and animal 
models. 
Mohan et al. performed long-term in vivo imaging of diamond nanoparticles in 
Caenorhabditis elegans and investigated their influence on this organism.61 When bare 
diamond nanoparticles were used to feed the worms in the absence of E. coli, the particles 
remained in the lumen even at 12 hours after feeding, and there was no uptake of the particles 
into the intestinal cells. However, when the diamond nanoparticles were surface modified with 
BSA or carboxymethyldextran (CMDx) before being fed to the worms, the majority of the 
coated nanoparticles were taken up by the intestinal cells, with very few remaining in the gut 
lumen region. In addition to these feeding studies, well-dispersed bare diamond nanoparticles 
were microinjected into the distal gonads of gravid hermaphrodite worms, followed by transfer 
of the worms to bacterial lawns. Fig. 14a shows the injection site. At 30 min after injection, the 
nanoparticles were dispersed in the distal gonad and oocytes. The diamond nanoparticles 
appeared in the cytoplasm of many cells in the early embryos but were predominantly present 
in the intestinal cells of the late embryos (Fig. 14b and c). This study yielded no evidence that 
the diamond nanoparticles caused any abnormal embryonic development.61 In comparison, 
silica nanoparticles have been found to induce intracorporal hatching of eggs in the parent 
worms.176 It was demonstrated that the diamond nanoparticles did not cause any detectable 
stress to the organism. The diamond-nanoparticle-targeted oocytes could grow in size and 
become mature oocytes. When these nanoparticle-containing oocytes were fertilized, the 
resulting embryos developed normally. During the observation period of 14 hours, the 
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nanoparticles were not excreted from the oocytes or embryos, and no abnormalities were 
observed during cell division, differentiation, or morphogenesis in embryogenesis.177 
To further investigate the toxicity of diamond nanoparticles, the lifespan and reproductive 
potential of worms that were treated with or without either dextran- or BSA-coated diamond 
nanoparticles were studied. The findings revealed that the lifespan and brood size of the treated 
and untreated worms were essentially the same.177 In comparison, silver nanoparticles have 
been found to affect these parameters and even to result in early death of the organism.178 
Measurements of ROS generation indicated that the diamond nanoparticles did not increase the 
amount of ROS produced relative to the untreated group.177 Similarly, Schrand et al. also found 
that nonfluorescent diamond nanoparticles did not increase ROS levels in neuroblastoma 
cells.179 To validate these findings that diamond nanoparticles do not generate ROS, further 
studies need to be performed to find out the reason as it is commonly believed that 
nanomaterials are capable of producing ROS. This may be very likely to relate to the size, 
surface chemistry and amount of the used diamond nanoparticles. It is hoped that the study can 
lead to findings about the control of ROS generation for different purposes. 
Following these studies in cell lines and worms, research on the safety of diamond 
nanoparticles was extended to explorations of the biodistribution of diamond nanoparticles in 
animal models. Rojas et al. used 18F to label nanodiamonds and investigated their distribution 
using positron emission tomography.180 The results showed that the nanoparticles were 
predominantly distributed in the lungs, spleen, and liver and excreted into the urinary tract. The 
addition of a surfactant such as PEG 8000 or Tween 80 did not significantly alter the pattern 
of organ uptake but did result in reduced urinary excretion and, correspondingly, increased 
blood bioavailability180 Very recently, Zhang et al. investigated the in vivo biodistribution and 
clearance of diamond nanoparticles labeled with the near-infrared dye XenoLight CF750 
following intravenous injection in mice.171 By means of whole-body imaging, it was observed 
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that 3 hours after injection, the nanodiamonds had predominantly accumulated in the liver (Fig. 
14d). In comparison, the delivery of free dye led to wide distribution. A quantitative analysis 
indicated some additional distribution in the spleen, lungs and kidneys (Fig. 14e). The 
accumulation peaked at 6 hours after injection, and the nanodiamonds had clearly been 
eliminated after 72 hours. Despite the fact that the nanoparticles predominantly accumulated 
in the liver, it was found that liver function was not adversely affected, by measuring alanine 
transferase (ALT), aspartate aminotransferase (AST) and alkaline phosphate (ALP) and 
performing a histological analysis. 
Although most studies have suggested that diamond nanoparticles demonstrate excellent 
biocompatibility and negligible toxicity, some results have indicated a negative influence of 
such materials. For example, nanodiamonds with sizes of 4-5 nm were found to lead to 
increased expression of p53, a DNA repair protein, within 2-4 hours of incubation with mouse 
embryonic stem cells.181 An increase in the expression of this protein is commonly observed 
during the initial stage of DNA damage. With the prolongation of incubation to 24 hours, 
increased expression of MOGG-1 was observed, indicating the breakage of DNA double 
strands. Unsurprisingly, the toxicity of nanodiamonds is affected by their surface properties. 
Oxidized diamond nanoparticles exhibit higher toxicity than do pristine/raw nanoparticles in 
terms of DNA damage. This has been demonstrated by observations that oxidized 
nanodiamonds resulted in increased expression of p53 and a higher level of apoptosis compared 
with pristine/raw nanoparticles. The elevated toxicity was ascribed to either the negatively 
charged carboxyl groups on the surfaces of the oxidized nanoparticles or the improved cellular 
uptake of the oxidized nanodiamonds. DNA damage might be caused by nanodiamond-
mediated oxidative stress.182 Vaitkuviene et al. found that at low concentrations of up to 100 
µg/ml, diamond nanoparticles did not significantly influence the metabolic activity of 
neuroblastoma SH-SY5Y cells. However, at a higher concentration of 150 µg/ml, the metabolic 
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activity of the neural cells was dramatically reduced.183 Despite these observations showing 
that diamond nanoparticles exhibit slight toxicity, it has been demonstrated that this material 
causes much less severe DNA damage compared with multi-walled carbon nanotubes 
(MWCNTs),181 and it is generally believed that nanodiamonds are more biocompatible and 
benign than most other nanostructures, including other carbon nanomaterials and 
semiconductor quantum dots.184, 185. This is, in fact, the greatest advantage of diamond 
nanoparticles, enabling their safe application in drug delivery, imaging and sensing. 
5. Vertically aligned diamond nanostructure arrays 
5.1. Intracellular drug delivery 
The efficient delivery of molecules and materials into living cells is not only essential for 
scientific studies of cell biology but also greatly useful for the development of novel 
therapies.186, 187 Delivering DNA and RNA into cells is necessary for gene therapy.188, 189 The 
delivery of fluorescence probes is often needed for cell biology research. The transport of 
proteins into cells is useful for intervening in cellular processes.190 Various techniques have 
been developed for these purposes, including biological, chemical, and physical approaches.26, 
191-197 Among them, physical methods possess unique advantages and are more suitable for 
certain applications. In particular, micro-injection has been widely and successfully applied to 
deliver various materials into the cytoplasm and even nuclei of cells.198, 199 Recently, to improve 
the throughput of conventional micro-injection, several vertically aligned nanostructure arrays 
have been demonstrated to act as high-throughput, efficient, and universal intracellular delivery 
platforms.200 For example, cells may be cultured on arrays of nanostructures such as silicon 
nanowires or aluminum oxide nanostraws. During culturing, the nanofeatures slowly penetrate 
into the cells, thereby enabling the intracellular delivery of molecules and materials such as 
DNAs, RNAs, peptides, and proteins.201-205 Different from these approaches, we reported the 
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use of ultra-small diamond nanoneedle arrays (Fig. 15a and b) for the active disruption of the 
cell membranes to facilitate the delivery of fluorescent probes and small molecule drugs.23, 27, 
206-208 In our methods, diamond nanoneedle arrays were brought into contact with cells grown 
on a substrate with a certain force or the cells were applied to the nanoneedles at a relatively 
fast speed, such that mechanical disruption could be immediately achieved. Early research in 
this field has been summarized in our previous reviews.26, 143, 209 Herein, emphasis will be 
placed on the very recent development of techniques for the delivery of a broader range of 
molecules and materials to more types of cells, including difficult-to-transfect cells, as well as 
the in vivo application of this type of technique. 
Regarding the use of diamond nanoneedle arrays for intracellular delivery, initially, a cell 
suspension was applied to vertically aligned nanostructures at a fast speed to induce disruption 
of the cell membranes to facilitate the transport of fluorescent probes or drug molecules into 
the cells.208 Later, centrifugation force was employed for precise control of the disruption of 
the cell membranes by the diamond nanoneedles. In this procedure, cells are cultured on a flat 
substrate in a well. Before intracellular delivery, the cell culture medium is removed and 
replaced with a medium containing the molecules or materials to be delivered. Then, a diamond 
nanoneedle array is introduced, with the needles pointing toward the cells, to cause mechanical 
disruption of the cell membranes. The disruption is controlled by the centrifugation force, 
which, in turn, is controlled by tuning the centrifugation speed. After the intracellular delivery 
process is complete, usually within a few minutes, fresh cell culture medium is added to the 
well to lift the nanoneedle array off the cells. The scheme is illustrated in Fig. 15c and d.23 To 
gain a better understanding of the mechanism by which intracellular transport is facilitated by 
diamond nanoneedle arrays, the delivery of calcein AM and ethidium homodimer-1 (EthD-1) 
to fibroblast cells and primary hippocampal neurons was investigated. Calcein AM is 
membrane permeable, can be cleaved by esterases in live cells, and exhibits green fluorescence. 
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EthD-1 is membrane impermeable, but it can enter membrane-comprised cells and diffuse to 
the nucleus, where it emits red fluorescence. Diamond-nanoneedle-treated cells exposed to 
these agents showed both red and green fluorescence. This indicates that successful cytosolic 
delivery of EthD-1 through comprised cell membranes can be realized by means of nanoneedle 
treatment without affecting cell viability. For the delivery of molecules to fibroblast cells and 
hippocampal neurons, the optimal centrifugation speeds are significantly different, likely 
because of the differing mechanical properties of the cell membranes. For fibroblast cells, the 
delivery efficiency of EthD-1 is approximately 5% at 300 rpm (12.8 x g, RCF), and it rapidly 
improves to approximately 80% at 500 rpm (35.5 x g). At 300 rpm, the treatment causes 
negligible cell damage. At 500 to 1000 rpm, the viability of cells still remains at approximately 
90%. For neurons, the delivery efficiency of EthD-1 is approximately 80% at a centrifugation 
speed of 300 rpm. A further increase in speed leads to dramatically increased cell death. 
Most attractively, diamond nanoneedle treatment can greatly facilitate the delivery of 
plasmid DNA into neurons, which are generally very difficult to transfect. The commonly used 
Lipofectamine transfection method offers a very low transfection efficiency of only 1-5% in 
primary neurons. Additionally, the protocol often takes several hours because of the 
endocytosis-based uptake of the DNA complexes. By contrast, with the aid of the diamond 
nanoneedle treatment of neurons, DNA-lipid complexes are able to enter these cells within a 
much shorter period of time (5-30 min). A transfection efficiency of approximately 45% can 
thus be consistently achieved in primary neurons. The method is high in throughput and results 
in fairly uniform transfection across the entire nanoneedle-array-treated area, as indicated in 
Fig. 16.23 The treated cells can still be maintained in long-term culture, allowing proper cellular 
development and stable GFP expression, as demonstrated by the staining of vesicular glutamate 
transporter 1 (vGlut1). These results indicate that the diamond nanoneedle treatment of cells is 
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a powerful method of achieving efficient, high-throughput intracellular delivery, particularly 
for difficult-to-transfect cell lines. 
Similar techniques, although with different materials for the vertical nanostructures, have 
also recently been used in a variety of applications. For example, carbon nanosyringe arrays 
have been employed to deliver small interfering RNAs, plasmids, and proteins to difficult-to-
transfect cells under centrifugation force.210 Biodegradable porous silicon nanoneedle arrays 
have even been used for drug delivery in vivo. In that work, human VEGF165 plasmid DNA 
was delivered to the muscles of mice, and the results were compared with those of the direct 
injection of the same amount of DNA. Both treatments induced gene expression of human 
VEGF165 for up to 7 days, but the expression level induced via nanoneedle application was, 
on average, higher than that induced via direct injection. Moreover, the nanoneedle-treated 
muscles displayed higher vascularization compared with the control group during two weeks 
of observation. Consequently, it was concluded that the neovascularization induced via 
nanoneedle application enables a surge in perfusion, whereas injection has no similar effect. 
The neovasculature in nanoneedle-treated muscles results in highly interconnected and 
structured vessels in close proximity to the surface, causing blood perfusion to increase by a 
factor of six. Evidently, nanoneedle treatment causes new blood vessels to form, with a 
functional effect. Inspired by these findings, we foresee that our diamond nanoneedle arrays 
may also be used for highly effective in vivo drug delivery in the future. Diamond nanoneedles 
possess significantly higher mechanical strength than silicon ones; therefore, a diamond-based 
technique is expected to be more reliable and reproducible and should achieve more consistent 
outcomes.  
5.2. Intracellular sensing 
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Because nanoneedles can pierce into cells, it would be advantageous to exploit this 
characteristic for intracellular sensing. Biodegradable porous silicon nanoneedle arrays have 
been applied to deliver pH-sensitive fluorescein isothiocyanate (FITC), with AlexaFluor 633 
(AF633) as a reference, to act as a ratiometric fluorescence sensor. This sensor was tested in 
the OE33 esophageal adenocarcinoma cell line (cancer cells) and the Het-1A cell line (healthy 
cells). The intracellular pH values of the OE33 and Het-1A cells were measured to be 6.7 and 
7.2, respectively. These results are consistent with those determined via a BCECF ratiometric 
fluorescence assay.211 Another example of a potential sensing application of nanoneedles is the 
intracellular sensing of protein. Cathepsin B (CTSB) is a protease protein that is often confined 
to the lysosomes and is highly expressed in many tumors.212 To determine the CTSB expression 
in cells, a fluorescent dye can be conjugated to nanoneedles using a CTSB-cleavable peptide. 
If there is CTSB expression in the cells, the peptide will be cleaved, causing the fluorescent 
dye molecules to be released in the cytosol. Using this method, it is possible to map intracellular 
CTSB activity in human tissue. In culture, this approach is able to provide single-cell mapping 
resolution, through which it is possible to distinguish cell phenotypes in mixed culture. These 
results indicate that nanoneedles show potential for further development for cancer diagnostics. 
In particular, for Barrett’s patients, such a nanoneedle sensor could enable sampling and 
analysis in the esophageal epithelium during endoscopy, which could make early diagnosis of 
cancer possible. 
Based on a similar principle, the intracellular level of NF-κB can also be determined using 
diamond nanoneedle arrays. NF-κB is a protein that found in almost all animal cells and is 
involved in cellular responses to stress or antigens. As a test case, when double-strand DNAs 
(dsDNA90) enter cells, NF-κB is released because of the activation of stimulator of interferon 
genes (STING). If the expression of NF-κB is detected, then the innate cellular immunity can 
be studied by targeting the host-defense response to pathogen molecules. For NF-κB fishing, 
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DNA aptamers (5′-GGGGAATCCCC-3′) are pre-conjugated to diamond nanoneedles before 
insertion into cells because they can specifically bind to NF-κB. Fig. 17a shows a schematic of 
the probing process using diamond nanoneedles inserted into the cell cytoplasm to fish for NF-
κB, which is generated upon the stimulation of dsDNA90.213 The NF-κB signaling dynamics 
in primary neurons can be studied by means of diamond nanoneedle fishing at various time 
points (Fig. 17c-d). The results show that the amount of NF-κB present significantly decreases 
over time after the initial STING activation. At the first instance of probing, the percentage of 
NF-κB-positive nanoneedles was 52.16.7%. This value rapidly decreased to 8.90.6% at 
more than 40 min after the initial delivery of dsDNA90. These results successfully demonstrate 
that diamond nanoneedle arrays can be conveniently applied to extract the dynamics of 
signaling components from living cells. 
5.3. Biocompatibility and toxicity 
For both intracellular delivery and sensing, vertical nanostructures of diamond or a similar 
material must pierce into cells. Such penetration can be realized by either culturing cells 
directly on these vertical nanostructure arrays or causing the nanostructures to actively pierce 
the cell membranes.  
Regarding the growth of cells on vertical nanomaterials, a number of studies have been 
performed to investigate the potential effect on the cells. Despite being impaled on the tips of 
silicon nanowires, cells can grow and divide over a period of several weeks. SEM images of 
primary rat hippocampal neurons on silicon nanowires have indicated that these cells can grow 
and build synaptic connections even with nanostructures penetrating into the neurons. After 
two weeks of culturing on nanowires, the investigated neurons were still able to fire action 
potentials upon current injection.203 However, some cell functions might be perturbed by 
culturing on such nanostructures for an extended period of time. For example, it has been 
36 
 
discovered that HeLa cells grow slowly and temporarily develop irregular contours when 
culturing on silicon nanowires and that the penetration of nanowires into the cells leads to lipid 
scrambling, although this can be reversed in healthy cells.203 In addition, Persson et al. found 
that if fibroblasts are cultured on vertically aligned nanostructures, cell division will be 
impaired, and ROS can be generated, leading to DNA damage.214 It has been reported that 
when mesenchymal stem cells are grown on vertical silicon nanowire arrays, the adhesion, 
proliferation and differentiation behaviors of these cells are distinctly different from those of 
cells grown on flat substrates.215 
Our studies have shown that when diamond nanoneedle arrays are used for intracellular 
delivery, this technique does not cause notable cell death compared with untreated cell groups, 
as confirmed by microscopy observations, MTT assays and measurements of the extracellular 
level of glucose-6-phosphate dehydrogenase (G6PD).20, 23, 208 By determining the amount of 
phosphorylated histone variant H2AX (pH2AX) in the treated cells, it was also found that 
diamond nanoneedle treatment did not cause double-strand DNA breaks. In this technique, 
although mechanical disruption to the cell membranes is required to facilitate the entry of 
materials and molecules into the cells, this disruption is not irreversible. To confirm this, cells 
were incubated with calcein AM and PI. Calcein AM can be transported into living cells, where 
it emits green fluorescence. PI does not permeate into living cells and can enter cells only when 
the cell membrane is comprised. To investigate whether mechanically disrupted cell 
membranes could recover, these two materials were added to the medium at different time 
points after the cells were treated with diamond nanoneedle arrays. A group of cells that was 
not subjected to diamond nanoneedle treatment was used as a control. The results are shown in 
Fig. 18. When calcein AM and PI were added to the medium immediately after nanoneedle 
disruption, the intracellular delivery was significantly improved compared with the control 
group. However, over time, this effect became increasingly weaker. After 40 min, the 
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intracellular delivery was identical to that in the control group. These observations indicate that 
cell membranes disrupted by diamond nanoneedles can quickly recover their integrity within a 
few tens of minutes. In addition to this study, the integrity of the cell membrane at 3, 6, and 24 
hours after diamond nanoneedle treatment was further confirmed by means of Image-iT DEAD 
Green viability stain. 
Although diamond nanoneedle treatment causes negligible cell death and double-strand 
DNA breaks, it does influence the physiology of cells. For example, such treatment can lead to 
cell apoptosis (Fig. 19).20 Compared with the untreated group, the population of apoptotic A549 
cells increased from 1.31% to 3.17%. When cells were co-treated with both nanoneedles and 
the anticancer drug cisplatin, the population of apoptotic cells increased from 11.54% to 
16.59%. This finding illustrates one of the reasons why the efficacy of cisplatin can be 
significantly enhanced when cells are also treated with diamond nanoneedles. It was also 
observed that diamond nanoneedle treatment could lead to elevated intracellular ROS 
production. However, these negative effects may be partially counteracted by the increase in 
the intracellular G6PD level that occurs upon nanoneedle treatment. The production of ROS 
may be induced by the depolarization of the mitochondrial membrane potential caused by the 
nanoneedles. After depolarization, this potential can slowly recover, reaching its original state 
by approximately 24 hours after diamond nanoneedle disruption. 
6. Conclusions and future outlook 
A wide range of nanomaterials have been developed for biomedical applications. To 
enable their future use in practical applications, it is very important to integrate their various 
advantages into a single system for optimal performance. Diamond is one such material that 
possesses collectively superior characteristics and therefore has attracted considerable interest 
in research on the properties and applications of nanostructures. Diamond nanoparticles that 
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contain NV- centers exhibit high absorption, near-infrared emission, ultra-high photostability, 
no photoblinking, excellent biocompatibility, surface tunability, and intrinsically stable 
emission, and these characteristics are unaffected by the size, surface modifications or 
environment of the nanoparticles. By virtue of these characteristics, such nanomaterials are 
ideal for long-term fluorescence bioimaging and particularly for quantitative analysis. More 
attractively, NV- centers are sensitive to magnetic fields, temperatures, ion concentrations, 
electric fields, and spin densities. Therefore, they can be used as probes to monitor changes in 
these parameters. In this respect, they show enormous potential to be used for MRI with 
nanometer resolution under ambient conditions, which would greatly expand the application 
scope of conventional MRI. The successful development of such technology will provide a 
powerful tool for studying biological tissues at the molecular level and will enable dramatic 
advancements in clinical healthcare applications. Vertically aligned diamond nanostructures 
have recently been applied for high-throughput intracellular delivery and sensing. Compared 
with chemical and biological techniques for these purposes, this physical tool has considerable 
advantages. For example, its application is universal, simple, high in throughput, cost-effective 
and safe and also enables the controllable delivery of materials to specific organelles within 
cells.  
Despite the great progress that has been made in the development of diamond 
nanomaterials, these materials are far from being ready for practical application. To realize this, 
great efforts will be required in the following aspects: (1) It is necessary to better understand 
the surface properties of diamond nanoparticles and their influence on the nanoparticles’ 
functionality and stability in biological environments such as blood because of the potential for 
interactions with hundreds of proteins. (2) Few studies have investigated the in vivo 
degeneration and fate of diamond nanoparticles. To this end, it is very important to understand 
their evolution over time in the body and their biodegradation mechanism. (3) Quantitative 
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studies must be performed to precisely determine the drug loading of diamond nanoparticles 
and their delivery efficiency to tumors. (4) For MRI specifically, it will be essential to explore 
means of ensuring the stability of the magnetic properties of NV- centers when they are located 
only a few nanometers below the surface, such that their spin properties are maintained. 
Another necessary future step will be to demonstrate ultra-high resolution MRI in samples of 
practical importance, such as single protein molecules and living tissues. In addition, NV 
centers can also be created in vertically aligned diamond nanostructures for intracellular 
sensing. (5) Given the robust photostability of NV centers, diamond nanoparticles have great 
potential for use in multipurpose applications such as precision image-guided therapies, and 
this possibility should be studied. (6) Research on the biocompatibility and toxicity of vertically 
aligned diamond nanoneedle arrays should be extended to more type of cells, and more 
physiological parameters need to be explored to understand the possible effects of diamond 
nanoneedles in a broad range of applications. (7) There is plenty of room for the further 
development of vertically aligned nanostructures to collect intracellular signals from cells for 
biological analysis and disease diagnosis. Last but not least, in vivo applications of vertically 
aligned diamond nanostructure arrays should be designed and tested. Because of the 
remarkable mechanical strength of diamond, when vertically aligned diamond nanostructures 
are used in applications requiring mechanical force, they are expected to achieve far superior 
outcomes compared with other types of vertical nanostructures. In this regard, comparative 
studies should be established, and computer modeling can be employed to explain the 
differences. These explorations are expected to offer tremendous opportunities to further the 
development of diamond nanomaterials toward their effective and safe application in drug 
delivery, bioimaging and biosensing. 
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Fig. 1 a. Characterisation of discrete 5-nm diamonds on a glass coverslip; b. Magnified AFM 
image and corresponding surface profile (inset) of a representative nanocrystal 5 nm in 
height;22 c and d. SEM images of vertically diamond nanoneedle arrays (The scale bar in c 
indicates 2 µm).20, 23 
  
49 
 
Fig. 2 Overview of the most important surface modification methods for covalently attaching 
molecules to diamond: The upper half shows different first steps that are performed to provide 
a homogeneous surface. Details on the synthesis for the different surface terminations can be 
found in the respective references: 134, 235, 36, 337, 38, 434, 539. The lower half shows different 
ways of attaching a linker molecule (R stands for the desired functional groups, e.g., NH2): 6
42, 
735, 36, 837, 934, 40, 1041. 
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Fig. 3 (a) The atomic structure of a single Nitrogen-Vacancy (NV) defect in diamond. 
Substituted Nitrogen atom (blue) bound to Vacancy site (white) in a diamond lattice (black). 
(b) Fluorescence emission from single NV defect showing zero-phonon-lines (ZPL) of NV- 
and NV0 characteristics. (c) Energy level structure of NV defect and the spin sublevels optical 
excitation 532 nm (green arrow), Fluorescence emission (red arrows 637–750 nm) non-
radiative decay processes (black dashed lines) and orange lines spin transitions driven by MW 
fields. (d) Optically detected Magnetic resonance (ODMR) spectrum of single NV spin and the 
corresponding Zeeman effect on magnetic field dependence.28 
  
a c 
b d 
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Fig. 4 Scanning probe magnetometry. (a) Diagram of the magnetic field imaging experiment. 
A nanoscale magnetic particle (red) is imaged with a single nitrogen-vacancy defect (green, 
within the blue nanocrystal) fixed at the scanning probe tip (black). (b) Optical image of a 
diamond nanocrystal attached to an AFM tip (view from the bottom). The scattered light image 
of the tip is overlapped with the fluorescence image of the nanocrystal. The bright spot 
(arrowed) represents fluorescence of a single nitrogen-vacancy defect. Fluorescence 
autocorrelation function (data not shown) shows a pronounced antibunching dip, indicating a 
single nitrogen-vacancy defect in the nanocrystal on the AFM tip. (c) Field reconstruction using 
the scanning probe single spin magnetometer. Top left, an AFM image of a nickel magnetic 
nanostructure prepared by electron beam lithography; bottom left, a magneto-optical image of 
the same structure, recorded using a single nitrogen-vacancy centre on the AFM tip as light 
source and magnetometer. Inset (right), the fluorescence signal from the scanned nitrogen-
vacancy centre attached to the apex of the AFM tip when resonant microwaves at 2,750 MHz 
are applied (the arrowed point corresponds to 5mT resonance line with the magnetic field tilted 
by 45º relative to the nitrogen-vacancy axis).81 
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Fig. 5 Characterization of single fluorescence nanodiamonds (FNDs). (a) Fluorescence 
lifetime measurements of 100-nm FNDs (green) and Alexa Fluor 546 dye molecules (blue). 
Fitting the time traces with two exponential decays reveals a fast component of 1.7 ns (4%) 
and a slow component of 17 ns (96%). The latter is four times longer than that (4 ns) of 
Alexa Fluor 546. (b) Typical time traces of the fluorescence from a single 100-nm FND 
(green), a single 35-nm FND (red), and a single Alexa Fluor 546 dye molecule attached to a 
single dsDNA molecule (blue). Note that no sign of photobleaching was detected within 300 
s of the continuous excitation for the FNDs.90 
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Fig. 6 Characterization of fluorescent nanodiamonds (FNDs). (a) Fluorescence spectra of 35-
nm FNDs suspended in water (1 mg ml-1 each), prepared with either 40-keV He+ or 3-MeV 
H+ irradiation. Inset: Fluorescence image of a 35-nm FND suspension excited by 532-nm 
laser light. (b) Fluorescence intensities of FNDs as a function of particle size at three different 
laser powers. Each data point is the mean of measurements for more than 15 different FNDs. 
The slopes of the linear fits vary from 2.65 to 2.95 over the power range used in the 
measurements. Inset: Fluorescence time trace (intensity normalized) of a 25-nm FND.80  
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Fig. 7 Observation of single FNDs in a HeLa cell. (a) Bright-field and epifluorescence images 
of a HeLa cell after uptake of 35-nm FNDs. Most of the uptaken FNDs are seen to distribute 
in the cytoplasm.90 (b) Epifluorescence image of a single HeLa cell after the FND uptake. An 
enlarged view of the fluorescence spots (denoted by ‘‘1’’ and ‘‘2’’) with diffraction-limited 
sizes (FWHM  500 nm) is shown in Inset. The separation between these two particles is 1 
m.90 (d) Three-dimensional trajectory (shown in pseudo-colour, right panel) and 
displacements of a single FND inside a cell over a time span of 200 s.86 (d) Subdiffraction 
resolution STED image and corresponding vertically binned STED image profile of a diamond 
particle with ~ 100 nm diameter showing five isolated NV- centres (red curve: Lorentzian fit). 
(e) SEM image of the same nanodiamond and overlay of the STEM image and the SEM image 
illustrating the relative dimensions.119 
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Fig. 8 The schematic representation of a molecular structure microscope. The NV spin sensor 
is scanned relative to the biomolecule either in the manner shown above or in swapped 
configuration. Spin density can be effectively mapped at various locations to reconstruct the 
molecular structure of isolated biomolecules in three dimensions.28 
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Fig. 9 Nitrogen–vacancy-based nanoscale thermometry. a, Schematic image depicting 
nanodiamonds (grey diamonds) and a gold nanoparticle (yellow sphere) within a living cell 
(central blue object; others are similar) with coplanar waveguide (yellow stripes) in the 
background. The controlled application of local heat is achieved by laser illumination of the 
gold nanoparticle, and nanoscale thermometry is achieved by precision spectroscopy of the 
nitrogen–vacancy spins in the nanodiamonds. b, Simplified nitrogen–vacancy level diagram 
showing a ground-state spin triplet and an excited state. At zero magnetic field, the |±1 
sublevels are split from the |0 state by a temperature-dependent zero field splitting (T). 
Pulsed microwave radiation is applied (detuning, ) to perform Ramsey-type spectroscopy. c, 
Comparison of sensor sizes and temperature accuracies for the nitrogen–vacancy quantum 
thermometer and other reported techniques. Red circles indicate methods that are biologically 
compatible. The open red circle indicates the ultimate expected accuracy for our measurement 
technique in solution.141 
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Fig. 10 a: Illustration of the preparation of lipid-coated diamond nanoparticle clusters loaded 
with water insoluble sorafenib. b, c, and d Tumour growth inhibition effects in BGC-823 gastric 
cancer cells induced tumour xeograft mice (20 mg/kg). b: The relative tumour volumes in 
tumour xenograft models treated with saline, sorafenib suspension, nanodiamond (ND) + 
sorafenib (Sora) and lipid-coated diamond nanoclusters loaded with sorafenib (SND) by oral 
gavage (20 mg/kg). c: The photographs of tumours from each group excised on day 23 after 
oral administration. d: The relative tumour weight in mice with treatment of sorafenib, ND + 
Sora and SND in comparison with saline group (**p < 0.01). e and f: Therapeutic efficacy of 
SND on suppressing the distant metastasis to liver (e) and kidney (f) in BGC-823 gastric cancer 
cells induced tumour xenograft mice. Mice were daily treated with saline, sorafenib suspension, 
ND + Sora and SND at 20 mg/kg of sorafenib by oral gavage. At the end point, the visually 
detected metastatic nodules in each tissue of liver and kidney were counted.150 
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Fig. 11 (a) Schematic representation of nanodiamond (ND) variants surface characteristic. (b-
d): ND-induced vascular barrier leakiness assists cancer therapy by promoting penetration of 
cancer drug across the vascular barrier. (b): Experimental scheme. (1) Vascular barrier was 
treated with ND variants to induce leakiness. (2) Following the induction of leakiness the ND 
variants were removed and the leaky vascular barrier was transferred to another well in which 
the MDA-MB-468 cancer cells were grown and (3) the doxorubicin (DOX) was added. (4) 
The excess DOX was removed along with the EC, followed by quantification of the amount 
of DOX successfully penetrating the vascular barrier and the DOX effect on the MDA-MD-
468. (c): ND variant treatments promotes the penetration of DOX across the vascular barrier. 
(d): Increase cancer cell (MDA-MB-468) cytotoxicity concomitant with the increase of DOX 
penetration over leaky vascular barrier. Fresh cell culture medium and DOX (320 nM) were 
added to single culture MDA-MB-468 cells to serve as negative and positive controls, 
respectively. Data are means ± S.D., n = 3, Student’s t-test, p < 0.05, ^Significant against 
untreated vascular barrier. *Significant against untreated MDA-MB-468 group.157 
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Fig. 12 a. Illustration of using PEI800 surface-modified nanodiamond (ND) for DNA delivery. 
b. Cytotoxicity assay of HeLa cultures with complexes formed by different carriers with pDNA 
at weight ratios from 1 to 30. c. ND-PEI800-mediated pLuc transfection in HeLa cells induces 
greatest pLuc expression. Maximum transfection efficiency was observed at a weight ratio of 
20 for ND-PEI800. Note the low transfection efficiency of ND alone and PEI800 alone 
compared to the ND-PEI800 vector. Data is represented as a mean ± standard deviation (N = 
2). An asterisk denotes particles with transfection efficiency lower than 1 RLU/mg of protein 
in the cell lysate.167 
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Fig. 13 (a) Synthetic scheme of multifunctional PTX-DNA/mAb@nanodiamonds (NDs). 
Sulfo-LC-SPDP was attached on to an aminated ND surface (ND-NH2), forming sulfhydryl-
reactive NDs (ND-SPDPs). Thiolated drug-oligonucleotide conjugates and thiolated mAbs 
were then simultaneously attached to ND-SPDPs. (b) Quantitative analysis of PTX-DNA@ND 
and PTX-DNA/mAb@ND internalization within cells. Flow cytometry analysis of fluorescein-
labeled oligonucleotides is representative of ND-conjugate internalization into MCF7 and 
MDA-MB-231 cells. Data is represented as the mean ±standard deviation (N = 2). (c) 
Cytotoxicity profi les of PTX (blue triangles), PTX-DNA@NDs (red squares) and PTX-
DNA/mAb@NDs (black diamonds) in respect to escalating equivalent PTX doses in MCF7 
and MDA-MB-231 cells after 48 h incubation ( n = 6). Corresponding IC 50 values are listed 
underneath.173 
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Fig. 14 Microinjection of bare fluorescence nanodiamonds (FNDs) into C. elegans. (A-C) 
Epifluorescence/DIC-merged images of an injected worm (A) and its progeny at the early (B) 
and late (C) embryonic stages. The FNDs dispersed in the distal gonad and oocytes at 
approximately 30 min after injection (A). Green arrows indicate bulk streaming of FNDs with 
cytoplasmic materials and the red triangle indicates the site of injection. Note that the injected 
FNDs are present in the cytoplasm of many cells in the early embryos (B) but predominantly 
in the intestinal cells of the late embryo (C). Scale bars are 10 μm.61 (D) representative whole-
body images of ICR mice after tail vein administration with 1.2 mg of XenoLight CF750-
labeled NDs or 30 fmol of XenoLight 750 (NS: normal silane; ND: nanodiamond). (E) 
quantification of NDs accumulated in mouse tissues at different time points after tail vein 
administration with XenoLight 750-labeled NDs with a dose of 80 µg per mouse (20 g) (n = 5 
at each time point). Data are respresented as means ± SD. The insets show organ-specifc 
imaging of ICR mice at 6 h after injection (Li, liver; S, spleen; Lu, lung; K, kidney).171 
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Fig. 15 (a) and (b) Characterization of diamond nanoneedle array. (a) Overall view (scale bar, 
10 mm) and (b) detailed view (scale bar, 2 mm) of a nanoneedle array by scanning electron 
microscopy. (c) and (d) Schematic of the nanoneedle array-based intracellular delivery system. 
(c) Illustration of the basic design and working principle. (d) The work flow of the delivery 
procedures using nanoneedle arrays. The interaction between nanoneedles and cells was 
precisely controlled by centrifugation-induced supergravity to achieve reliable and efficient 
cytosolic delivery. Briefly, the culture medium was first removed, and replaced with basal 
medium containing materials to be delivered (fluorescent dye, dextran, antibody, nanoparticle, 
DNA, and so on). The solution volume was just enough to cover all the cells and to prevent 
cells from drying. A nanoneedle array was then placed onto the solution with nanoneedles 
facing towards cells, leaving a thin layer of solution between the nanoneedles and the cells. 
The whole setup was placed in a centrifuge and spun at various speeds. After centrifugation, 
extra basal medium (containing cargo materials at desired concentrations) was immediately 
added to the culture well to lift off the nanoneedle patch. After 5–30 min incubation at 37 C, 
fresh culture medium was used to wash off extra materials and to culture the cells for further 
analysis. The nanoneedle patch was then cleaned with piranha solution for reuse.23 
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Fig. 16 Efficient cytosolic delivery of plasmid DNAs in neurons. (a) Stitched phase-contrast 
image of a neuron culture (6–7 DIV) treated by a nanoneedle patch. (b) Stitched fluorescent 
images of neurons transfected with GFP. In a,b, red squares indicate the area covered by the 
nanoneedle patch, scale bar, 1.6 mm. (c) Enlarged view of the yellow line boxed regions in a. 
(d) Enlarged view of the yellow line boxed regions in b. (e) Merged image of neuron cells 
combining phase-contrast and GFP channels; scale bar, 50 mm. (f) Comparison of the 
transfection efficiency between nanoneedle-based technique and traditional lipofection method 
at different incubation times, error bars indicate s.e.m. from three independent experiments. *p 
< 0.01, determined by analysis of variance.23 
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Fig. 17 Diamond-nanoneedle-assisted intracellular “molecular fishing”. (a) Schematic of the 
centrifugation controlled intracellular insertion and probing process. (b-d) Interrogation of 
STING activated innate immune response in primary hippocampal neurons. (b) Phase-contrast 
image of cultured primary hippocampal neurons (9 days in vitro). Scale bar, 50 μm. (c) 
Combined fluorescence images showing colocalization of NF-κB speckles (red) with diamond-
nanoneedles (green) at 0, 7, 15, and 40 min after intracellular delivery of dsDNA90. Scale bar, 
20 μm. Enlarged views of the boxed region in the top row are shown in the bottom row. Scale 
bar, 5 μm. (d) Quantitative analysis of NF-κB positive nanoneedles with or without the STING 
activator (dsDNA90) in neuron cells at different experimental time points. Error bars indicate 
s.e.m. from three independent experiments. *P<0.001 by ANOVA analysis.213 
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Fig. 18 Cytosolic delivery of calcein-AM and PI in A549 cells. a) Calcein-AM (left) and PI 
(right) fluorescent images of living A549 cells when the chemicals were added at different time 
points after the cells being treated with nanoneedles. b) Quantification of calcein-AM 
fluorescent intensity of different groups. c) Quantification of PI fluorescent intensity at 
different time points. Untreated A549 cells were set as a control group.20 
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Fig. 19 Flow cytometry analysis of apoptosis and necrosis of A549 cells. a) Untreated cells; b) 
Cells treated with a diamond nanoneedle array (ND) alone; c) Cells incubated with 5 μg mL−1 
of cisplatin for 24 h. d) Cisplatin was added to a cell suspension with a concentration of 5 μg 
mL−1 and the suspension was applied to a diamond nanoneedle array for treatment for 5 min. 
Subsequently, the cell suspension was collected and cultured in a 96-well plate for 24 h. The 
analysis was conducted after 24 h incubation. For all groups, A549 cells were stained and 
analysed by 488 nm excitation with 530/30 nm and 575/24 nm bandpass filters and collected 
by means of a standard 100 μL min−1 collection rate. Early apoptotic cells are shown in the 
lower right quadrant, and necrotic cells are shown in the upper left quadrant.20 
 
